Kenneth Galbraith - 15 Jan 2022 Form 4 Insider Report for Zymeworks Inc.

Role
Chair, President & CEO, Director
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Jan 2022
Net transactions value
$0
Form type
4
Filing time
18 Jan 2022, 05:25:42 UTC
Previous filing
17 May 2021
Next filing
23 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +500,000 $0.000000 500,000 15 Jan 2022 Common Shares 500,000 $14.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.